Lunit, a leading provider of artificial intelligence (AI)-powered solutions for cancer diagnostics and therapeutics, has announced two supply contracts that mark its strategic expansion into the East and Southeast Asian region.

South Korean startup Lunit will supply its Lunit INSIGHT CXR for chest abnormality detection and Lunit INSIGHT MMG for mammography analysis to the Chung Shan Medical University (CSMU) in Taiwan and Gleneagles Hospital in Singapore, respectively. Gleneagles plans to enhance screening accuracy and operational efficiency by seamlessly integrating Lunit's cutting-edge technology into its breast screening workflow.

Compared to Taiwan's current screening programme, which relies on low‐dose computed tomography (LDCT) for screening high-risk individuals such as smokers or those with a family history of lung cancer, CSMU aims to validate Lunit INSIGHT CXR for potential integration into the national cancer screening programme. The goal is to assess its ability to detect individuals more accurately and efficiently, potentially expanding the screening to a broader group beyond high-risk individuals. This approach could significantly advance Taiwan's efforts to enhance early detection and improve outcomes in lung cancer screening.